Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHRISTOPHER D STILL

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1710935739
CMS profile
169276
Location
DANVILLE, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$116,112.26

101 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Lilly USA, LLC $54,485.43 54
Novo Nordisk Inc $28,197.22 20
Boehringer Ingelheim Pharmaceuticals, Inc. $24,323.13 16
Currax Pharmaceuticals LLC $8,316.12 8
Regeneron Pharmaceuticals, Inc. $750.00 2
Baxter Healthcare $40.36 1

Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHRISTOPHER D STILL

NPI 1710935739 · CMS profile ID 169276

Allopathic & Osteopathic Physicians / Internal Medicine

DANVILLE, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1710935739?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHRISTOPHER D STILL, NPI 1710935739, CMS profile ID 169276. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1710935739?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). CHRISTOPHER D STILL, NPI 1710935739, CMS profile ID 169276. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1710935739?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
CHRISTOPHER D STILL, NPI 1710935739, CMS profile ID 169276, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1710935739?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

101 matching records · $116,112.26 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 101 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–101 of 101.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $1,185.7501/01/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1188999382 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $79,730.58 108
PY2020 $47,541.16 33
PY2021 $42,231.26 40
PY2022 $79,631.52 71
PY2023 $19,655.93 19
PY2024 $56,938.38 68
PY2025 $116,112.26 101

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $198.99 1
PY2025 Principal investigator $1,208,496.73 303
PY2024 Recipient $2,170.90 11
PY2024 Principal investigator $1,070,331.38 175
PY2023 Recipient $291.00 1
PY2023 Principal investigator $1,298,313.37 177
PY2022 Recipient $436.00 1
PY2022 Principal investigator $1,790,773.10 62
PY2021 Principal investigator $438,728.53 143
PY2020 Recipient $145.50 1
PY2020 Principal investigator $289,883.27 36
PY2019 Recipient $705.39 1
PY2019 Principal investigator $575,668.97 71

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

304 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,614.15 12/19/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184279120
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $5,427.46 12/12/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080566
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 12/12/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080568
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 12/12/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080570
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 12/12/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080572
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 12/12/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080574
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 12/12/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080576
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 12/12/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080578
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 12/12/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080580
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 12/12/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080582
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 12/12/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080584
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 12/12/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080586
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 12/12/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080588
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 12/12/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080590
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 12/12/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080592
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 12/12/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080594
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 12/12/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080596
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,589.65 12/11/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184274466
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $44.80 12/05/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080554
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $6,693.00 12/05/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080556
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $89.60 12/05/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080558
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $6,693.00 12/05/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080560
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $29.58 12/05/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080598
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $18.69 12/05/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080600
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,149.50 12/05/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080602
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,930.80 12/04/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184269077
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,190.08 11/25/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080700
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,789.00 11/25/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080706
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,190.08 11/25/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080708
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,190.08 11/25/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080722
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,904.00 11/25/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080728
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,190.08 11/25/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080732
Principal investigator 1 Ethicon Endo-Surgery Inc. $60,000.00 11/18/2025 Non-covered Recipient Entity
GEISINGER CLINIC
SWIFT Trial Surgical Weight Loss to improve functional status trajectories following Total Knee Arthroplasty No dispute reported 06/30/2026 1174996013
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,851.05 11/14/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184261379
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,860.50 11/07/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184259041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,465.20 10/16/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184250695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 10/16/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184250697
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,023.36 10/16/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184250699
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,523.58 10/16/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184250701
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 10/16/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184250703
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 10/16/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184250705
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $440.00 10/16/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184250707
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $6,693.00 10/08/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080562
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $268.80 10/08/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080564
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,789.00 10/08/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080694
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,904.00 10/08/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080720
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $956.16 10/07/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080696
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $1,200.00 10/07/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080698
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $379.00 10/07/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080702
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $1,358.00 10/07/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080704
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $39.68 10/07/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080710
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,904.00 10/07/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080712
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $956.16 10/07/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080714
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,789.00 10/07/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080716
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,789.00 10/07/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080718
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $39.68 10/07/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080724
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,904.00 10/07/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080726
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $1,800.00 10/07/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080730
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,568.35 10/03/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184244713
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $55.14 10/01/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080520
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $27.57 10/01/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080522
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $106.61 10/01/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080524
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $16.50 10/01/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080526
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $70.80 10/01/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080528
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $27.57 10/01/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080530
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $121.84 10/01/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080532
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $270.02 10/01/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080534
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $270.02 10/01/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080536
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $270.02 10/01/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080538
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $270.02 10/01/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080540
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $270.02 10/01/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080542
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $270.02 10/01/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080544
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $270.02 10/01/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080546
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $270.02 10/01/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080548
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $270.02 10/01/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080550
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $270.02 10/01/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080552
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,812.65 09/23/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184241666
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,614.15 09/18/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184240564
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $956.16 09/13/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080684
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,904.00 09/13/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080686
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $379.00 09/13/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080688
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $956.16 09/13/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080690
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,789.00 09/13/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080692
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31,749.20 09/12/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184236600
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $133.12 09/10/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080486
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $1,349.04 09/10/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080488
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $494.08 09/10/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080490
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $256.00 09/10/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080492
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $345.60 09/10/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080494
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $313.60 09/10/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080496
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $320.00 09/10/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080498
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $6,693.00 09/10/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080500
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $1,239.68 09/10/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080502
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $100.00 09/10/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080504
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $89.60 09/10/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080506
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $6,693.00 09/10/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080508
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $6,693.00 09/10/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080510
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $44.80 09/10/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080512
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $5,102.19 08/27/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080610
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $566.91 08/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080608
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $31.15 08/13/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080604
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $629.90 08/13/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080606
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,330.25 08/07/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184226165
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,684.92 08/07/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184226167
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,198.50 07/22/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184217813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,909.55 07/17/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184217122
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,913.98 07/17/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184217124
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 07/17/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184217126
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,500.00 07/17/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184217128
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,808.00 07/17/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184217130
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,726.30 07/17/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184217132
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $871.71 07/17/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184217134
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,247.90 07/10/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184214408
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,760.00 07/04/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184212891
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $141.60 07/01/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080484
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,142.40 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080354
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,142.40 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080356
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,767.04 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080358
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,142.40 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080360
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,767.04 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080362
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,767.04 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080364
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,142.40 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080366
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,142.40 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080368
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,142.40 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080370
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,923.52 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080372
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,142.40 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080374
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,767.04 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080376
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,142.40 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080378
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080380
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080382
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080384
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080386
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080388
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080390
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080392
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080394
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080396
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080398
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080400
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,767.04 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080402
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,142.40 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080404
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,767.04 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080406
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,142.40 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080408
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,767.04 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080410
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $6,693.00 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080412
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $268.80 06/25/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080414
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,789.00 06/21/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080660
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $39.68 06/21/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080664
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $39.68 06/21/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080672
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,904.00 06/21/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080674
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $25,341.58 06/20/2025 Non-covered Recipient Entity
Geisinger Health System
Long Term Extension Trial of Setmelanotide No dispute reported 06/30/2026 1240080682
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,071.80 06/12/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184206289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $808.00 06/12/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184206291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,827.96 06/12/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184206293
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,812.25 06/05/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184204133
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $6,693.00 06/04/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080416
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $520.96 06/04/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080418
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $1,239.68 06/04/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080420
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $66.56 06/04/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080422
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $247.04 06/04/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080424
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $128.00 06/04/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080426
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $345.60 06/04/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080428
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $100.00 06/04/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080430
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $320.00 06/04/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080432
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,198.50 05/22/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184197643
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $602.00 05/22/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184197645
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,068.00 05/22/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184197647
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,205.40 05/15/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184194669
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,090.52 05/15/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184194671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,047.16 05/15/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184194673
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,789.00 05/15/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080656
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,789.00 05/15/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080658
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $956.16 05/15/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080662
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,904.00 05/15/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080666
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,904.00 05/15/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080668
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $956.16 05/15/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080670
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $600.00 05/15/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080676
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $956.16 05/15/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080678
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $956.16 05/15/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080680
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,627.35 05/08/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184193767
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $6,698.52 05/02/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080434
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $313.60 05/02/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080436
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $1,239.68 05/02/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080438
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,817.50 04/28/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184190641
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,568.35 04/15/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184183334
Principal investigator 1 Eli Lilly and Company $97.20 04/10/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187883504
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,760.00 04/08/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184181974
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $70.80 04/02/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080476
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $5.00 04/02/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080478
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $106.61 04/02/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080480
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $55.14 04/02/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080482
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $6,693.00 03/24/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080324
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,479.36 03/24/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080326
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $268.80 03/24/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080338
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $6,693.00 03/21/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080298
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $100.00 03/21/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080312
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $224.00 03/21/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080330
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,479.36 03/21/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080352
Recipient Eli Lilly and Company $198.99 03/20/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187871653
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,243.00 03/19/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184174504
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $17,983.41 03/17/2025 Non-covered Recipient Entity
Geisinger Health System
Long Term Extension Trial of Setmelanotide No dispute reported 06/30/2026 1240080740
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,904.00 03/13/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080612
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $39.68 03/13/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080614
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $956.16 03/13/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080616
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,789.00 03/13/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080618
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $956.16 03/13/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080620
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $15,000.00 03/13/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080622
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,481.60 03/13/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080624
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,904.00 03/13/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080626
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,481.60 03/13/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080628
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $956.16 03/13/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080630
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $5,120.00 03/13/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080632
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,904.00 03/13/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080634
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,481.60 03/13/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080636
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $39.68 03/13/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080638
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,481.60 03/13/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080640
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,400.00 03/13/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080642
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $39.68 03/13/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080644
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,789.00 03/13/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080646
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,789.00 03/13/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080648
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $1,165.00 03/13/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080650
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $956.16 03/13/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080652
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $39.68 03/13/2025 Non-covered Recipient Entity
Geisinger Health System
Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway No dispute reported 06/30/2026 1240080654
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $429.50 03/11/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184170852
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,142.40 03/07/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080258
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,142.40 03/07/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080262
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,142.40 03/07/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080264
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 03/07/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080272
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,767.04 03/07/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080276
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,142.40 03/07/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080292
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,142.40 03/07/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080300
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,142.40 03/07/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080302
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,767.04 03/07/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080306
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 03/07/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080314
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 03/07/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080318
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,767.04 03/07/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080328
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,767.04 03/07/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080336
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3,714.56 03/07/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080340
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $898.45 03/04/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184156686
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $6.00 03/03/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080474
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,873.35 02/25/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184155426
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $10,483.41 02/24/2025 Non-covered Recipient Entity
Geisinger Health System
Long Term Extension Trial of Setmelanotide No dispute reported 06/30/2026 1240080736
Principal investigator 1 Eli Lilly and Company $111,840.09 02/18/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187881686
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,320.50 02/18/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184154240
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $13,386.00 02/14/2025 Non-covered Recipient Entity
Geisinger Clinic
DAYBREAK: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080266
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $4,000.00 02/14/2025 Non-covered Recipient Entity
Geisinger Clinic
DAYBREAK: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080280
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,100.00 02/14/2025 Non-covered Recipient Entity
Geisinger Clinic
DAYBREAK: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080286
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $9,900.00 02/14/2025 Non-covered Recipient Entity
Geisinger Health System
Long Term Extension Trial of Setmelanotide No dispute reported 06/30/2026 1240080734
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,796.90 02/11/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184152980
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $45.69 02/04/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080466
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $60.92 02/04/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080468
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $82.71 02/04/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080470
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $30.46 02/04/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080472
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $141.60 02/04/2025 Non-covered Recipient Entity
Geisinger Health System
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080742
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $88.74 02/03/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080514
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $43.61 02/03/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080516
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $5,039.20 02/03/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080518
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,728.20 01/28/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184149802
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $121,180.00 01/28/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184149804
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $7,061.51 01/24/2025 Non-covered Recipient Entity
Geisinger Clinic
DAYBREAK: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080274
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $6,693.00 01/24/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080278
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $313.60 01/24/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080288
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $4,958.72 01/24/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080296
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $100.00 01/24/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080344
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $1,322.24 01/24/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080350
Principal investigator 1 Ethicon Endo-Surgery Inc. $801.44 01/22/2025 Non-covered Recipient Entity
GEISINGER CLINIC
SWIFT Trial Surgical Weight Loss to improve functional status trajectories following Total Knee Arthroplasty No dispute reported 06/30/2026 1174996024
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $4,958.72 01/22/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080260
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $247.04 01/22/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080268
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $320.00 01/22/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080284
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $576.00 01/22/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080304
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $256.00 01/22/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080310
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $133.12 01/22/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080316
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $313.60 01/22/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080320
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $6,693.00 01/22/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080334
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $53.76 01/22/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080342
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $25.00 01/22/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080346
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,728.20 01/21/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184149070
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,120.00 01/21/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184149072
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,466.00 01/21/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184149074
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,900.00 01/21/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184149076
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,350.00 01/21/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184149078
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $12,983.41 01/21/2025 Non-covered Recipient Entity
Geisinger Health System
Long Term Extension Trial of Setmelanotide No dispute reported 06/30/2026 1240080738
Principal investigator 1 Ethicon Endo-Surgery Inc. $862.00 01/17/2025 Non-covered Recipient Entity
GEISINGER CLINIC
SWIFT Trial Surgical Weight Loss to improve functional status trajectories following Total Knee Arthroplasty No dispute reported 06/30/2026 1174996002
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $6,693.00 01/13/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080270
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $66.56 01/13/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080282
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $247.04 01/13/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080290
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $2,479.36 01/13/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080294
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $53.76 01/13/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080308
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $25.00 01/13/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080322
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $128.00 01/13/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080332
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $448.00 01/13/2025 Non-covered Recipient Entity
Geisinger Clinic
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080348
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $27.57 01/02/2025 Non-covered Recipient Entity
Geisinger Clinic
DAYBREAK: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080440
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $55.14 01/02/2025 Non-covered Recipient Entity
Geisinger Clinic
DAYBREAK: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080442
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $27.57 01/02/2025 Non-covered Recipient Entity
Geisinger Clinic
DAYBREAK: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080444
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $27.57 01/02/2025 Non-covered Recipient Entity
Geisinger Clinic
DAYBREAK: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080446
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $15.23 01/02/2025 Non-covered Recipient Entity
Geisinger Clinic
DAYBREAK: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080448
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $15.23 01/02/2025 Non-covered Recipient Entity
Geisinger Clinic
DAYBREAK: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080450
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $27.57 01/02/2025 Non-covered Recipient Entity
Geisinger Clinic
DAYBREAK: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080452
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $27.57 01/02/2025 Non-covered Recipient Entity
Geisinger Clinic
DAYBREAK: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080454
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $27.57 01/02/2025 Non-covered Recipient Entity
Geisinger Clinic
DAYBREAK: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080456
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $46.80 01/02/2025 Non-covered Recipient Entity
Geisinger Clinic
DAYBREAK: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080458
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $16.50 01/02/2025 Non-covered Recipient Entity
Geisinger Clinic
DAYBREAK: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080460
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $3.84 01/02/2025 Non-covered Recipient Entity
Geisinger Clinic
DAYBREAK: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080462
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $14.75 01/02/2025 Non-covered Recipient Entity
Geisinger Clinic
DAYBREAK: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080464